Clinical trial
Immunogenicity and Safety of Pentaxim as 3 Doses Primary Vaccination Followed by…
NCT00453570 · Sanofi, Industry · Completed
Key facts
| NCT number | NCT00453570 |
|---|---|
| Title | Immunogenicity and Safety of Pentaxim as 3 Doses Primary Vaccination Followed by a Booster Dose at 18 Months |
| Lead sponsor | Sanofi, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Diphtheria, Tetanus, Haemophilus Influenzae Type b, Pertussis, Poliomyelitis |
| Intervention type | Biological |
| Interventions | Diphtheria, Tetanus, Polio, Acellular Pertussis and Hib, & Acellular Pertussis Combined, Absorbed |
| Enrollment | 792 |
| Start date | Mar 1, 2007 |
| Primary completion | Dec 1, 2008 |
| Completion | Jan 1, 2009 |
| First posted | Mar 29, 2007 |
| Last update posted | Apr 17, 2012 |
| Countries | China |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: